Semax by prescription in the US

Semax is a short chain of seven amino acids, the building blocks of protein. It is made in a lab.

It is built from a small piece of ACTH, a hormone the body makes. Three amino acids at one end are different, which is thought to help it resist breakdown. Studies describe it as lacking the hormone effects of ACTH.

You may see two forms: semax free base and semax acetate. The FDA treats them as two different ingredients. Semax is a common name, not an official US drug name.

Semax is a registered medicine in Russia, sold as nasal drops. It is not FDA approved for any use, and no FDA-approved drug contains it.

In the US it is promoted online for memory and focus, anxiety, depression, stroke recovery and many other uses. The FDA found too little evidence for the uses it reviewed, as the evidence section below explains.

Compounding is when a licensed pharmacy makes a drug for one patient on a prescription. Under federal law, a 503A pharmacy can usually only use ingredients that pass one of three tests. The ingredient is part of a drug the FDA has approved, has a USP monograph, or is on the FDA's 503A bulks list. Semax passes none of them.

From September 29, 2023, to April 22, 2026, the FDA kept semax on its Category 2 list. That list flags ingredients that may pose significant safety risks. Semax came off it after the groups that nominated it withdrew. HHS says neither step changed its legal status.

On July 24, 2026, the FDA's compounding advisory committee voted in favor of adding semax to the 503A bulks list. According to RAPS, a group that reports on drug regulation, the vote was 8 to 5. FDA staff had advised against it. The vote is advice only, and the FDA has not made a final decision.

On October 30, 2026, HHS published a notice in the Federal Register, FR Doc 2026-22192. HHS Secretary Robert F. Kennedy, Jr. signed it. The notice itself does not name semax. The HHS policy it points to lists six peptides, and semax is one of them.

HHS says it does not intend to take enforcement action against a state-licensed pharmacy, federal facility or licensed physician that compounds semax under the policy's conditions. This lasts until a final FDA rule decides whether semax goes on the 503A bulks list.

This is not FDA approval and it is not a final rule. The notice calls the policy a draft and takes public comments for two weeks. HHS says the policy is not binding and may be revisited if a safety or quality problem appears.

For semax, the policy covers one route: use in the nose. Semax shots, capsules and creams are outside the policy. The policy names the free base form of semax, not semax acetate.

The pharmacy needs a valid prescription for you by name. It cannot sell semax to anyone without one.

Each product may contain only one active ingredient. Blends, such as semax mixed with selank, another peptide, fall outside the policy.

The raw peptide must come from a maker registered with the FDA. Each lot needs a certificate of analysis. It must show tests for identity, purity, strength and contaminants such as endotoxins and heavy metals.

The label must say: "This is a compounded drug product. Not for resale." The pharmacy must report serious side effects and quality problems to the FDA through MedWatch.

Start with a visit, in person or by video, with a licensed prescriber. They should review your health history, your current medicines and why you want semax. They decide whether a prescription is right for you.

In most states, the prescriber must be licensed in the state where you are at the time of the visit. Ask which states they are licensed in before you book.

The prescription then goes to a state-licensed 503A compounding pharmacy. The pharmacy makes the product for you and ships it or has it ready to pick up. Not every pharmacy ships to every state, so ask before you pay.

Check that what you are offered is a nasal product with semax as the only active ingredient. A semax shot or a semax and selank blend is not covered by the HHS policy.

In a proper prescription route, a prescriber approves you before you can check out for the peptide. A site that sells semax with no prescription, or as "research use only", is not using this route.

Much of the research on semax has been done in rats, mice and cells. Those studies suggest effects on the brain and nerves, on pain and on mood. Animal results do not show that it works in people.

Human studies exist, but most are small, come from Russia and are published in Russian. Many had no placebo group. Some gave semax together with other treatments, so its own effect is hard to separate.

The FDA reviewed semax for stroke-related brain injury, migraine and a facial nerve pain called trigeminal neuralgia. It found too little evidence that semax works for any of them. In the one small migraine and nerve pain study it reviewed, semax did not relieve pain for most people.

The FDA did not count several Russian stroke studies, because no full English text was available. One of them, from 2018, followed 110 stroke patients and reported faster recovery with semax. Its abstract does not describe a placebo group.

Human data on memory and focus come from a few small studies in healthy adults. They are too small to show a real benefit.

No trials of semax are registered on ClinicalTrials.gov. The FDA found no human studies of semax given as a shot.

The FDA says there is not enough clinical information to describe how safe semax is. It found no human studies of how the body absorbs and clears semax. It also found no long-term animal studies of cancer risk.

Human safety data cover only use in the nose. Most of those studies did not report on side effects at all. HHS notes that none of them reported harm.

One study suggested semax may slow blood clotting. The FDA said this raises a bleeding concern, mainly for people at risk of bleeding or taking medicines that raise that risk. In mice, semax also boosted the effect of amphetamine on dopamine, a brain chemical. The FDA said this pattern is typical of addictive drugs, and found no studies of whether semax itself is addictive.

The FDA has one side effect report for semax. A person had eye pain and burning after using semax nasal drops bought online, and went to the hospital.

Ask your prescriber: Which states are you licensed in? What is the evidence for my condition? Is it safe with my other medicines, including any that affect bleeding? What side effects should I watch for, and who do I contact if I have one?

Ask the pharmacy: What is your name, and are you a 503A pharmacy licensed in my state? Who made the raw peptide, and is that maker registered with the FDA? Can I see the certificate of analysis for my lot, including endotoxin tests? Is semax the only active ingredient? If you have a side effect, tell your prescriber and report it to the FDA through MedWatch.

We checked 250 US sellers across the six peptides in the HHS policy. 59 ranked providers list semax. What they charge: $99 to $229 a month, for the 2 of 5 that post a price and sell by the month. Few providers post a semax price, so ask before you book. Another 13 list semax but are not ranked, each with the reason on this page.

We also found 3 sellers offering semax with no real prescription check, often as "research use only". We do not rank them or name them here.

Legal checks carry the most weight in our scores. We look for a state license, a prescription before checkout, single-ingredient products, routes the policy covers, and any FDA warning letters. Quality checks include a named, FDA-registered ingredient maker and batch certificates of analysis. We also check whether prices and the states served are public.

Prices and fees change often. Check them, and the states served, on the provider's own page before you book a visit. The research for this page was done on October 29, 2026.